inPractice® - Cobicistat

Agents Used in Antiretroviral Therapy

Authors: Philip Grant, MD (More Info)
Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
Last Reviewed: 4/9/19 (What's New)

Summary

Cobicistat is a CYP3A inhibitor used as a pharmacologic booster for atazanavir, darunavir, and elvitegravir at a daily dose of 150 mg (Table 13)^{[FDA Cobicistat]}
Baseline CrCl should be assessed before initiating treatment
- When cobicistat is administered with tenofovir DF or tenofovir AF, baseline urine glucose and urine protein should also be assessed^{[FDA Cobicistat; FDA COBI/EVG/FTC/TAF]}

Action required

Login now to access all of your entitled content
or
View additional options to gain access to this content

Keywords: Drug-Drug Interactions, Initial Antiretroviral Therapy, Special Populations, Treatment Complications